Home › Companies › PHIO

Phio Pharmaceuticals Corp.

PHIO Lead: Phase 1 2 Biotech Distilled articles ↓

Oncology Nucleic Acid

Most recent annual filing: 2026-03-15

Pipeline (4 active programs)

PH-762

Nucleic Acid Target: PD-1

Cutaneous Squamous Cell Carcinoma Phase 1 intratumoral
Melanoma Phase 1 intratumoral
Merkel Cell Carcinoma Phase 1 intratumoral

PH-894

Nucleic Acid Target: BRD4

Undisclosed indication Preclinical

Technology platforms

INTASYL

Proprietary self-delivering small interfering RNA (siRNA) gene silencing platform. Chemically modified siRNAs with spontaneous cellular uptake — no formulations, nanoparticles, or electroporation required. Targets a broad range of cell types and tissues; designed for immuno-oncology applications including direct-to-tumor injection and adoptive cell therapy (ACT). Demonstrated preclinical activity against PD-1, BRD4, CTLA-4, TIGIT, and CTGF.

Targets: PD-1, BRD4, CTLA-4, TIGIT, CTGF

Biotech Distilled coverage (2)

2026-05-08 UPDATE: Phio Pharmaceuticals (PHIO) - The ORR Keeps Shrinking 🔒 Paid
2026-04-15 Phio Pharmaceuticals (PHIO) - Scientific Deep Dive for PH-762 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.